What Disability Does Shane Burcaw Have

What Disability Does Shane Burcaw Have

Shane Burcaw has spinal muscular atrophy type 2, a genetic neuromuscular disorder that affects motor neurons and causes progressive muscle weakness. SMA type 2 is one of the most common forms of spinal muscular atrophy, and it typically appears in infancy or early childhood. People with this condition often require mobility aids, respiratory support, and ongoing medical care throughout life.

SMA is caused by mutations in the SMN1 gene, which leads to a deficiency of survival motor neuron protein. This protein loss damages the nerve cells that control voluntary muscle movement. Shane Burcaw has spoken publicly about living with SMA type 2, describing the daily realities of using power wheelchairs and managing breathing and coughing functions.

How Shane Burcaw Manages SMA Type 2

Burcaw uses a power wheelchair for mobility and relies on assistive technology to communicate, write, and engage with audiences. He has shared details about respiratory care routines, including airway clearance devices and monitoring for respiratory infections, which are critical for people with SMA type 2.

In addition to personal management strategies, Burcaw has partnered with organizations focused on neuromuscular disease awareness and support. He uses social media and public speaking to explain SMA, challenge misconceptions, and highlight the importance of accessibility in education, workplaces, and public spaces.

SMA Awareness and Treatment Landscape

SMA affects roughly 1 in 10,000 live births, and SMA type 2 accounts for a significant share of diagnoses. Disease-modifying therapies such as nusinersen, onasemnogene abeparvovec, and risdiplam have been developed to address the underlying genetic cause of SMA. These treatments aim to increase functional SMN protein and improve motor outcomes, though they do not cure the condition.

Regulatory agencies including the U.S. Food and Drug Administration have approved multiple SMA therapies in recent years, and health systems continue to evaluate access and long-term outcomes. Organizations such as the Muscular Dystrophy Association provide resources for patients, families, and clinicians navigating SMA diagnosis and treatment decisions.